跳至主要内容
临床试验/NCT04409691
NCT04409691Unknown1 期

A Clinical Study on the Treatment of Kaposiform Hemangioendothelioma (KHE) With Kasabach-Merritt Phenomenon (KMP) by Hormone Shock and Sirolimus Maintenance

Shanghai Children's Medical Center1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2020年7月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
发起方
入组人数
20
试验地点
1
主要终点
response to treatment

研究概览

简要总结

a phase I trial focusing on safety and efficacy of prednison shock plus sirolimus maintenance in treating Kaposiform hemangioendothelioma (KHE) with Kasabach-Merritt phenomenon (KMP)

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
— 至 12 Years(Child)
性别
All
接受健康志愿者

入选标准

  • Kaposiform Hemangioendotheliomas with Kasabach-Merritt Phenomenon
  • 0 - 12 years of age at the time of study entry
  • Male or female
  • Consent of parents (or the person having parental authority in families)
  • Signed and dated written informed consent

排除标准

  • with hematological diseases
  • with other solid tumors
  • with hypertension, diabetes, adrenal insufficiency, neurological diseases, liver and kidney
  • dysfunction, and cardiopulmonary insufficiency
  • with tuberculosis,cytomegalovirus and Epstein-Barr virus infection before the treatment

研究组 & 干预措施

prednison group

Active Comparator

干预措施: prednison (Drug)

prednison+sirolimus group

Experimental

干预措施: prednison and Sirolimus (Drug)

结局指标

主要结局

response to treatment

时间窗: 6 months after taking the drug

Complete Response: platelets counts is greater than 100×10\^9/L. significant volume reduction is greater than 80%. Fibrinogen levels at 2-4g/L. The surface skin of the tumor is lighter or the tumor is softer significantly. Partial Response: platelets counts is greater than 40×10\^9/L. significant volume reduction is greater than 50%. Fibrinogen levels at less than 50% reduction from baseline. The surface skin of the tumor and palpation of the tumor have no change or less change. No Response: platelets counts is less than 40×10\^9/L. significant volume reduction is less than 50% or the tumor is bigger. Fibrinogen levels at grater then 50% reduction from baseline. The surface skin of the tumor is darker or the tumor is harder.

次要结局

  • side effect rate(6 months after taking the drug)

研究者

发起方
Shanghai Children's Medical Center
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验